Producer
IPCA Laboratories
Indian API and formulation manufacturer; one of the key tretinoin API producers. Major supplier of generic API to US, EU, and global markets. BSE/NSE listed. Ratlam (Madhya Pradesh) and other facilities. IPCA was subject to FDA import alert in 2015 affecting US supply of multiple APIs -- demonstrating how a single enforcement action against one Indian API manufacturer can create shortage of multiple drugs simultaneously.
1
Inputs supplied
1
Goods downstream
1
Facilities
0
Stories
What they make
1 input IPCA Laboratories supplies
Click an input to see every good that depends on it, every country that produces it, and every other company in the supply chain.
Where it shows up
Goods downstream
Essential goods that depend on something IPCA Laboratories makes — pick one to see the full supply chain.
What else they do
Business segments
The company's full revenue map — where this supply-chain role fits within their broader business.
Anti-Malarial APIs & Formulations
30%Cardiovascular & Pain APIs
28%Generic Formulations (International)
25%Domestic India Business
17%
Intelligence
What's known
Sourced claims about this company's role in supply chains — chokepoints, concentration, incidents, dual-use connections.
Origin2022
IPCA Laboratories Limited, founded in 1949 in Ahmedabad as the Indian Pharmaceutical Company Ahmedabad, is one of the world's largest suppliers of anti-malarial APIs and formulations to WHO, UNICEF, and global health programs — a position that placed it at the center of a geopolitical episode in 2020. When US President Trump claimed hydroxychloroquine (a chloroquine derivative primarily used for malaria and autoimmune diseases) as a COVID-19 treatment without clinical evidence, global demand for the drug surged. India, which produces approximately 70% of the world's hydroxychloroquine API, temporarily banned exports in March 2020 to protect domestic supply. After diplomatic pressure from the Trump administration, India reversed the ban and permitted exports. IPCA, as one of India's primary hydroxychloroquine API producers, was at the center of this episode — a pharmaceutical company whose anti-malarial production suddenly became a diplomatic bargaining chip between the world's two largest democracies. IPCA had separately been on an FDA import alert since 2015 for manufacturing quality violations, preventing it from selling in the US market while remaining a major WHO-approved supplier to global health programs — illustrating how the same company can simultaneously be excluded from one regulatory system while being integral to global public health supply chains.
IPCA Laboratories Limited ↗